title: Evaluation of safety parameters and changes in serum concentration in liver transplant recipients treated with doxorubicin during the anhepatic period.
abstract: OBJECTIVE
  Because of the recurrence of hepatocellular carcinoma (HCC) at the graft after liver transplantation, circulating HCC cells may be present during the anhepatic period. Intravenous doxorubicin (DOX) is used during the anhepatic period to combat these cells; however, pharmacokinetics data have been poorly analyzed. This study aims to investigate DOX administration during the anhepatic period.
  
  
  METHODS
  We administered 5 mg/m(2) DOX immediately after liver removal and compared serum DOX concentrations at several intervals during the anhepatic period in patients who underwent liver transplantation because of liver cirrhosis and HCC (n = 3) and patients who underwent liver resection owing to HCC with portal vein tumor thrombi (n = 5). We also measured serum DOX concentrations and pharmacokinetic parameters in transplant patients that received 3-15 mg/m(2) DOX (n = 3 per dose level). We evaluated transplant patients' adverse drug reactions and survival.
  
  
  RESULTS
  At 10 and 30 min after DOX administration, serum DOX concentrations were elevated two- to threefold in transplant patients versus resection patients. Dose escalation in transplant patients exhibited a prolonged T½ in the one-compartment model and T½ β in the two-compartment model, as well as a dose-dependent elevation of the area under the curve. No obvious adverse drug reactions were noted at 3-15 mg/m(2) DOX. In transplant patients, 5-year recurrence-free survival was 68.8 %; overall survival was 100.0 %.
  
  
  CONCLUSIONS
  During the anhepatic period, serum DOX concentrations were elevated two- to threefold, T½ was prolonged dose dependently, and up to 15 mg/m(2) DOX could be safely administered
authors.forename: Shogo
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Wada
authors.forename: Naoki
authors.initials: N
authors.lastname: Hama
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Akita
authors.forename: Koichi
authors.initials: K
authors.lastname: Kawamoto
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Eguchi
authors.forename: Koji
authors.initials: K
authors.lastname: Umeshita
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Doki
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nagano
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D006528:Carcinoma, Hepatocellular / Q000517:prevention & control* / Q000601:surgery; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D005260:Female; D006207:Half-Life; D006801:Humans; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000601:surgery; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D011446:Prospective Studies; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin